



梅斯

MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock code : 2415



2026

INTERIM REPORT

CONTENTS

Chapter	Page
Corporate Information	2
Business Overview	4
Financial Highlights	10
Management Discussion and Analysis	11
Interim Condensed Consolidated Statement of Profit or Loss	31
Interim Condensed Consolidated Statement of Comprehensive Income	32
Interim Condensed Consolidated Statement of Financial Position	33
Interim Condensed Consolidated Statement of Changes in Equity	35
Interim Condensed Consolidated Statement of Cash Flows	36
Notes to Interim Condensed Consolidated Financial Information	38





CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Directors

Dr. Zhang Fabao (張發寶博士) (*Chairman of the Board*)
Dr. Li Xinmei (李欣梅博士) (*Chief Executive Officer*)
Mr. Wang Shuai (王帥先生) (*Co-Chief Executive Officer*)
Mr. Cheng Liang (程亮先生)

Non-executive Directors

Mr. Yan Shengfeng (閻盛楓先生)
Ms. Wang Xin (王欣) (*resigned on 6 February 2026*)

Independent Non-Executive Directors

Ms. Liu Tao (劉濤女士)
Mr. Yu Mingyang (余明陽先生)
Mr. Lau Yiu Kwan Stanley (劉耀坤先生)

JOINT COMPANY SECRETARIES

Mr. Yang Chun (楊春先生)
Ms. Kwan Sau In (關秀妍女士) (*ACG, HKACG*)

AUDIT COMMITTEE

Ms. Liu Tao (劉濤女士) (*Chairwoman*)
Mr. Yu Mingyang (余明陽先生)
Mr. Lau Yiu Kwan Stanley (劉耀坤先生)

REMUNERATION COMMITTEE

Mr. Yu Mingyang (余明陽先生) (*Chairman*)
Dr. Zhang Fabao (張發寶博士)
Ms. Liu Tao (劉濤女士)

NOMINATION COMMITTEE

Mr. Lau Yiu Kwan Stanley (劉耀坤先生) (*Chairman*)
Dr. Li Xinmei (李欣梅博士)
Mr. Yu Mingyang (余明陽先生)

AUTHORISED REPRESENTATIVES

Dr. Li Xinmei (李欣梅博士)
Ms. Kwan Sau In (關秀妍女士) (*ACG, HKACG*)

AUDITORS

Ernst & Young
(Certified Public Accountants
Registered Public Interest Entity Auditor)
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

HONG KONG LEGAL ADVISER

Eric Chow & Co. (in Association with
Commerce & Finance Law Offices)
3401, Alexandra House, 18 Chater Road
Central
Hong Kong

PRC LEGAL ADVISER

Commerce & Finance Law Offices
12-14th Floor
China World Office 2
No. 1 Jianguomenwai Avenue
Beijing 100004
China

REGISTERED OFFICE

89 Nexus Way
Camana Bay
Grand Cayman, KY1-9009
Cayman Islands

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Floor 3, Lane 425
Yishan Road, Xuhui District
Shanghai
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1928, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong



PRINCIPAL BANKS

China Everbright Bank
Changde Branch
1/F, No.1518, Xinzha Road
Jing'an District
Shanghai

Shanghai Pudong Development Bank Co., Ltd.
Shanghai Pilot Free Trade Zone Branch
2/F, Pufa Mansion, No. 588, Pudong South Road
Pudong New District
Shanghai

China Construction Bank Co. Ltd.
Shanghai Longcao Road Branch
No. 69-75, Longcao Road
Xuhui District
Shanghai
PRC

Bank of Shanghai Co., Ltd.
Minhang Branch
No. 1885, Qixin Road
Minhang District
Shanghai
PRC

China Merchants Bank Co., Ltd.
Shanghai Branch
11/F, No. 1088, Lujiazui Ring Road
Pudong District
Shanghai
PRC

CMB Wing Lung Bank Limited
CMB Wing Lung Bank Building
45 Des Voeux Road Central
Hong Kong

PRINCIPAL SHARE REGISTRAR

Ogier Global (Cayman) Limited
89 Nexus Way
Camana Bay, Grand Cayman
KY1-9009, Cayman Islands

HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

STOCK CODE

2415

COMPANY'S WEBSITE

https://ir.medsci.cn/zh_cn



BUSINESS OVERVIEW

BUSINESS REVIEW AND OUTLOOK

In the first half of 2026, the pharmaceutical and healthcare industry continues to face certain challenges in the short term, driven by multiple factors such as policies, market conditions, and industry structural adjustments. However, the long-term development trend of the industry remains stable, with digital and intelligent transformation deepening continuously. The application of artificial intelligence in professional scenarios such as medical research, clinical support, marketing, and data insights has accelerated significantly. At the national level, policy support has been consistently strengthened. The Outline of the 15th Five-Year Plan for National Economic and Social Development (《中華人民共和國國民經濟和社會發展第十五個五年規劃綱要》) has designated biomedicine as a key emerging pillar industry for development, further elevating the industry's strategic position and laying a solid foundation for long-term high-quality growth.

During the Reporting Period, the Group's overall performance experienced a slight decline due to the phased adjustments in our physician platform solutions business. However, our core businesses, including digital marketing, real-world clinical study, and data and artificial intelligence, all continued to grow, with our business mix being continuously optimized. Artificial intelligence has become a key driver of the Group's strategic transformation.

During the Reporting Period, the Group accelerated its transformation from a traditional physician platform to an AI-native physician platform. The habit of physicians using AI for medical information retrieval, evidence-based evidence acquisition, professional learning, and scientific research has been gradually established. The user base and token consumption of the Group's AI-powered physician product, DeepEvidence, both demonstrated rapid growth, with overall scale increasing by approximately 250% year-on-year and approximately 160% quarter-on-quarter. During the first half of 2026, the cumulative token consumption of the Group's AI platform approached the trillion-level mark, reflecting the continued improvement in user engagement frequency and application depth. Meanwhile, the DeepEvidence API has begun to be adopted by various healthcare industry institutions, indicating that the Group's AI capabilities are progressively extending from the platform side to the broader industry ecosystem.

In the field of medical research, the Group continues to advance the development of its research-grade AI product, SeekEvidence. By leveraging artificial intelligence to assist with literature retrieval, evidence analysis, and research workflows, the Group aims to enhance the efficiency and research output of medical research users, while further refining its AI product portfolio that spans clinical practice, medical research, and industrial applications for physicians.

As of the end of the Reporting Period, the Group's physician platform ecosystem, hospital collaboration network, and enterprise client base continued to be strengthened. The platform had accumulated over 5.82 million registered users, approximately 3.56 million certified physicians, and coverage of approximately 71% of associate-chief physician and chief physicians. The Group has cumulatively served 628 pharmaceutical and medical device companies, achieving 100% coverage of the global Top 20 pharmaceutical and medical device companies. Its service network covers over 2,000 medical institutions and continues to extend into county-level and primary healthcare settings. Leveraging its continuously expanding ecosystem coverage and data accumulation, the Group has consistently strengthened its precision evidence-based and decision-support capabilities for hospitals, experts, pharmaceutical companies, and researchers, facilitating the translation and application of high-quality medical evidence.



During the Reporting Period, the Group deeply embedded artificial intelligence technologies across its entire internal operational workflow, including product R&D, content production, project delivery, market research, and data insights, systematically enhancing R&D and production efficiency as well as cost-effectiveness. In the content production phase, AI-assisted generation significantly shortened the production cycle of medical content. In the project delivery phase, the adoption of intelligent tools effectively improved per-capita output and the standardization of delivery processes. In internal operations, automated workflow optimization continued to reduce management costs.

For the six months ended 30 June 2026, the Group achieved total revenue of RMB117.5 million, representing a period-on-period decrease of 6.2%; gross profit of RMB61.3 million, representing a period-on-period decrease of 20.8%; and net profit of RMB10.6 million, representing a period-on-period decrease of 19.7%. The decrease in revenue was mainly attributable to the reduced demand for simple language-based clinical research due to the popularization of AI technology, with revenue from physician platform solutions decreasing by 30.1% period-on-period; the decrease in gross profit was mainly attributable to the decline in the revenue proportion of the high-margin physician platform solutions, as well as the downward trend in project pricing against the backdrop of industry cost containment. During the period, through AI-driven efficiency enhancement and refined management, the Group's selling and distribution expenses, administrative expenses and R&D expenses decreased by 29.0%, 19.5% and 26.3% period-on-period, respectively, effectively buffering the impact of the decline in gross profit on profitability.

Looking ahead to the second half of 2026, the Group will continue to focus on the deep integration of artificial intelligence with professional medical scenarios, accelerating the extension of AI capabilities from product tools to actual business workflows. The Group will continue to enhance product capabilities such as DeepEvidence and SeekEvidence, and will launch AI-native data insight products tailored to the actual needs of pharmaceutical companies, further applying AI to areas including market insights, medical insights, physician behavior analysis, and marketing decision-making, thereby driving the upgrade of our digital marketing business to AI-driven digital marketing. As pharmaceutical companies continue to increase their acceptance of AI applications, the Group will further explore the deployment of AI in clients' internal business processes and professional work scenarios. Leveraging the Group's accumulated strengths in physician ecosystem, professional medical content, real-world study, healthcare data, and artificial intelligence, we will expand our AI service capabilities for industry clients.

At the same time, the Group will proactively explore new business directions, including the development of healthcare data assets, compliant circulation, and trading. On the basis of ensuring data security, privacy protection, and compliant operations, we will continue to enhance our capabilities in data governance, data productization, and AI applications, and explore new business models that combine healthcare data with artificial intelligence.

The Group will continue to advance its business upgrade around its three core capabilities: the physician platform, healthcare data, and artificial intelligence. As AI gradually moves from trial and exploration to broader business applications in the pharmaceutical and healthcare industry, the Group will prudently seize industry opportunities, continue to optimize its business structure and resource allocation, improve the operating quality of its core businesses, and cultivate new long-term growth drivers.



BUSINESS OVERVIEW

PHYSICIAN PLATFORM SOLUTIONS

The Group operates online professional physician platforms in China. As at 30 June 2026, our platform had approximately 3.6 million registered physician users and our average number of unique registered users, including all registered users such as physicians, nurses, pharmacists and other non-healthcare professionals, that accessed our MedSci platform in each month during the Reporting Period reached approximately 3.1 million during the Reporting Period, which further consolidated our position as the professional physician platform. Our MedSci platform also features a high percentage of experienced physician users with the title of associate-chief physician (副主任醫師) and above, as well as a professional physician platform with active users. The total number of registered physician users on our MedSci platform who had the title of associate-chief physician and above represented approximately 71% of the total number of physicians in China who had obtained the title of associate-chief physician and above, based on the latest published information from the National Health Commission of China. As at 30 June 2026, our MedSci platform covered 42 research areas, including 776,000 entries of medical information, representing an increase of 38,000 entries as compared to that as at 30 June 2025; and there were also 144,500 user communities and 10,150 physician communities. Our MedSci platform is accessible through multiple channels such as website, mobile application, WeChat mini-program and WeChat public account. Such platform proactively engages physicians through means such as email, phone calls, WeChat, and WeChat groups. Contents available on our platform are principally and independently published by the Group. Furthermore, third parties, including pharmaceutical and medical device companies, industry associations, and individual self-media, are provided with ancillary support for their release of information.

In terms of business, the Group is making strenuous efforts in advancing AI-powered physician platform solutions: by leveraging AI to enhance the information integration and detailing capabilities, physicians are able to obtain the necessary professional contents more rapidly and conveniently, thereby proactively reducing users' time spent on searching and obtaining information, reducing the number of redundant communities, as well as enhancing professionalism and accuracy of the platform, hence consolidating its position as an authoritative physician platform in the industry. Besides, through extensive application of AI at business level, the Group proactively reduced its reliance on labor-intensive services, realizing the transformation of the platform business from labor-powered to AI-powered, thus significantly enhancing its efficiency and ability for sustainable growth.

As at 30 June 2026, the Group had provided clinical research solutions to 115 hospitals/299 departments.

For the six months ended 30 June 2026, the total revenue from the physician platform solutions business amounted to approximately RMB32.7 million, representing a period-on-period decrease of approximately 30.1%. Such decrease was mainly attributable to the popularization of AI technology that reduced the demand for certain simple language-based clinical research. Looking forward, we will further optimise this business segment. The Group is actively developing intelligent agent products tailored to the specific needs of physicians at different levels, providing them with comprehensive intelligent clinical research services, thereby laying a foundation for future business growth.



EVIDENCE-DRIVEN PRECISION OMNI-CHANNEL MARKETING SOLUTIONS

The Group's precision omni-channel marketing mainly features academic-driven digital marketing, which, unlike traditional advertisement-based digital marketing models, emphasizes evidence-based and professional approaches rather than merely focusing on display volume or click-through rates. Due to a high reliance on professional academic resources and data analysis, this model has higher academic costs. As such, customers only opted for the Group's services for their key products or core projects in the past. However, in light of policy incentives, the anti-corruption campaign in the medical sector and the implementation of volume-based procurement policies, companies' demand for compliant, efficient and evidence-based services increased rapidly, and the value of the Group's business model has gained widespread recognition.

During the Reporting Period, revenue from the precision omni-channel marketing solutions business remained steady, while the fast-paced growth in demand for precision omni-channel marketing solutions recorded by the Company during the Reporting Period is expected to be reflected in revenue in future financial period due to the time gap between the Group's receipt of customer orders on one hand, and recognition of revenue upon delivery of the ordered solution and services on the other. The Group recorded revenue of RMB58.1 million for the Reporting Period, representing a year-on-year increase of approximately 3.4%, and its proportion of total revenue increasing from 44.8% to 49.4%. Such increase was attributed to the accelerated transition of domestic pharmaceutical companies towards evidence-driven marketing models, which gradually became the mainstream in the industry.

The Group persists in the flexible adoption of digital and on-ground marketing, and chooses the best strategies according to the stages of product lifecycles. In the early stages of launching innovative drug products, the digital academic marketing team collaborates with the ground sales teams to achieve the omni-channel coverage; while in the mature stage, with a focus on value-based healthcare orientation, the Group explores the academic highlights and clinical application differences of products, in an effort to help to match products with suitable patient groups, promote rational use of drugs in clinical settings and facilitate the recognition of the value of the products, hence benefitting both the patients and enterprises.

As at 30 June 2026, the Group had 669 active customers, including 582 core pharmaceutical, biotechnology, and medical device enterprise clients. During the Reporting Period, the revenue retention rate for the Group's top 10 customers was 100%. Among the Group's top 20 customers, 12 were multinational pharmaceutical companies and 18 were listed companies.

RWS SOLUTIONS

In the area of RWS solutions, the Group provides pharmaceutical and medical device enterprises with high-quality and cost-effective post-marketing clinical research solutions, including real-world studies, pharmacovigilance studies, pharmacoeconomics research, and innovative device registration studies.

During the Reporting Period, the revenue from the Group's RWS solutions business was approximately RMB20.4 million, representing a period-on-period increase of 22.6%. This increase was primarily attributable to (i) the Group's proactive efforts in reducing its inventory orders; and (ii) enhanced overall efficiency of RWS through AI applications.

During the Reporting Period, the Group executed 182 projects, and the current inventory orders decreased from RMB173 million at the end of 2025 to RMB151 million as at 30 June 2026.

DATA AND ARTIFICIAL INTELLIGENCE SOLUTIONS

MedSci Healthcare elevates its data and artificial intelligence capabilities to a strategic level. In addition to extensive application of artificial intelligence internally to enhance efficiency of business and quality of deliveries, the Group also actively promotes its artificial intelligence capabilities to the market for serving its customers.



BUSINESS OVERVIEW

Currently, artificial intelligence is still in a phase that mainly involves investment and development, resulting in pressure on the Group's short-term profits to a certain extent. However, the Group has begun to achieve rapid revenue conversion, which provides strong support for subsequent realization of benefits from artificial intelligence. We are now empowering customers with AI intelligence, offering comprehensive services covering training, marketing, big data governance, medical research and writing of clinical documents to enhance customers' digital intelligence capabilities and competitiveness. As of now, we have accumulated a group of seed customers and application cases, laying a solid foundation for our large-scale expansion in the next phase.

This segment will create synergy with physician platform solutions and precision omni-channel marketing solutions, and become a new driver for future growth, allowing continuous exploration of AI application in the entire medical value chain, ultimately establishing a "multi-agent collaboration" digital intelligence ecosystem.

During the Reporting Period, the data and artificial intelligence solutions business had 14 customers, with a revenue of RMB6.3 million, representing a period-on-period increase of approximately 11.2%.

OUTLOOK

The Group is well poised to be a pioneer and leader in the wavefront of the rapid transformation of China's pharmaceutical industry. Looking ahead, the Group will continuously introduce innovative AI and evidence-driven applications and solutions to capitalize on the enormous market opportunities in China and beyond. From digitalization to full scale upgrade to digital intelligence, the Group will extensively apply artificial intelligence technology to empower the healthcare industry. The Group will also speed up the AI reconstruction of our internal operations and AI expansion to external services. These initiatives are set to comprehensively enhance our service quality and efficiency, speed of delivery and standardization level so as to provide better experiences to our clients.

Vision 1: Strengthening Precision Omni-channel Marketing to Support High-Quality Development of Innovative Drugs

As the pioneer provider of precision omni-channel marketing solution in China's pharmaceutical sector, MedSci Healthcare seized the opportunity brought by the recovery of the industry and aptly rode on the trend of pharmaceutical enterprises' switching to evidence-driven marketing model. The relevant businesses saw significant growth and our professional capabilities attained recognition across the market. On the policy front, the National Healthcare Security Administration and the National Health Commission of the People's Republic of China jointly issued the Several Measures to Support the High-Quality Development of Innovative Drugs (《支持創新藥高質量發展的若干措施》) in July 2025, emphasizing their support to innovative drug full chain and the value of real world study (RWS). In 2026, policy support was further deepened. The Outline of the 15th Five-Year Plan for National Economic and Social Development (《中華人民共和國國民經濟和社會發展第十五個五年規劃綱要》) designated biomedicine as a key emerging pillar industry for development. The General Office of the State Council issued the Several Opinions on Improving the Drug Pricing Mechanism (《關於健全藥品價格形成機制的若干意見》), which explicitly calls for improving the framework, rules, and procedures for real-world study of pharmaceuticals, and encourages and supports the conduct of real-world research on drugs included in the National Reimbursement Drug List and the National Commercial Health Insurance Innovative Drug List. Additionally, the National Healthcare Security Administration initiated a new round of adjustments to the National Reimbursement Drug List and the National Commercial Health Insurance Innovative Drug List in 2026, introducing for the first time a "pre-submission" mechanism for innovative drugs, further shortening the cycle for innovative drugs to enter the reimbursement system, which created a new driving force to the industry. Leveraging on its long history of development, MedSci Healthcare has constructed a pharmaceutical value ecosystem which integrates RWS platforms, top-notch experts and digitalized channels. Such ecosystem will take full advantage of the national policy to explore a new round of development opportunities. Looking into the future, the Group will continue to upgrade its omni-channel marketing solutions, enhance the evidence drivers, further improve our holistic, full chain, full cycle service capabilities to comprehensively enable innovative drugs to enter into a new phase of quality development.



Vision 2: Full AI Enablement to Drive the Intelligent Transformation of Research and Healthcare

The first half of 2026 marks a pivotal term for the Group in the commercialization of AI. Aligning with the global trend of “AI for Research(AI4R)”, the Group has accelerated the integration of AI technologies across its entire value chain both in internal operations and external services, driving a comprehensive upgrade from digital to intelligent capabilities. The Group continues to collaborate with leading overseas AI technology partners to incorporate advanced capabilities, combining them with its deep understanding of medical scenarios and its extensive medical expertise to develop localized, innovative applications and build a differentiated portfolio of intelligent products. Currently, certain AI services have already achieved scaled revenue, with expectations of continued rapid growth in the future. At the policy level, the National Health Commission, together with four other departments, jointly issued the Implementation Opinions on Promoting and Regulating the Application Development of Artificial Intelligence + Healthcare (《關於促進和規範「人工智能+醫療衛生」應用發展的實施意見》), which clarifies the policy direction and regulatory requirements for the development of AI applications in healthcare, providing clear institutional guidance for the industry’s growth. Looking ahead, the Group will continue to increase R&D investment in the core algorithms underlying SeekEvidence and DeepEvidence, further deepen collaborations with pharmaceutical companies, medical institutions and healthcare management organizations, and leverage technological innovation to reduce the cost of medical communication. Its goal is to build a competitively leading intelligent evidence-based medicine service platform, creating long-term value for shareholders.

Vision 3: Two-Wheel Driven Ecological Empowerment to Build a New Ecosystem for the Globalised Pharmaceutical Industry

MedSci Healthcare is committed to the “digitalization + healthcare” two-wheel driven model and will further consolidate our globalization development strategy. The Group is evolving from standalone agent solution offerings toward a “multi-agent collaboration” model, so as to realize intelligence collaboration across different teams and different scenarios for higher business adaptability and creativity. On the technology acquisition front, the Group continues to engage with advanced AI technology resources from overseas, deeply integrating internationally leading artificial intelligence capabilities with vertical healthcare scenarios to form an innovation model of “global technology + local application.” In 2025, the Group established its Southeast Asia headquarters in Singapore and continued to position itself to deepen its presence in the Southeast Asian market in the first half of 2026. It aims to empower clients in the region with AI technologies, medical expertise, and operational capabilities, accelerating regional resource integration and differentiated competitiveness. At present, China’s innovative drug going-global efforts have entered an accelerated phase. In the first half of 2026, the total value of out-licensing (BD) transactions for Chinese innovative drugs reached approximately US\$110.0 billion, with the full-year transaction volume expected to exceed US\$150 billion. The going-global model is also evolving from traditional licensing transactions to a global partnership model characterized by “co-development and co-commercialization”, opening up significant opportunities for the Group’s international business development. In the future, the Group will continue to strengthen empowerment to innovative pharmaceutical enterprises for their path to internationalization by attaining our full-chain service capabilities covering market research, clinical trial support to pharmacovigilance, market access and pricing strategies, digital marketing and academic promotion. We aim to support Chinese pharmaceutical enterprises to go global. Through a closed-loop business model integrating content, services, and products, the Group will continue to enhance the resilience of our supply chain as well as our international service models and technologies in an effort to reinforce the ecosystem of the global pharmaceutical industry. We are committed to developing into and becoming an influential listed company in the global arena.



FINANCIAL HIGHLIGHTS

	For six months ended 30 June		Period-on-period movement*
	2026 (RMB'000) (Unaudited)	2025 (RMB'000) (Unaudited)	%
Revenue	117,451	125,246	(6.2)
Cost of sales	(56,121)	(47,767)	17.5
Gross profit	61,330	77,479	(20.8)
Profit for the period	10,638	13,239	(19.7)
Profit attributable to owners of the parent	10,638	13,239	(19.7)

* Period-on-period movement% represents a comparison between the six months ended June 30, 2026 and the six months ended June 30, 2025.

REVENUE BY SOLUTION CATEGORY

	2026		2025		Period-on-period movement*
	RMB	%	RMB	%	%
(RMB in thousands, except percentages)					
Precision Omni-channel Marketing Solutions	58,052	49.4	56,140	44.8	3.4
Physician Platform Solutions	32,728	27.9	46,828	37.4	(30.1)
Real-world clinical study ("RWS") Solutions	20,390	17.4	16,631	13.3	22.6
Data and artificial intelligence Solutions	6,281	5.3	5,647	4.5	11.2
Total	117,451	100.0	125,246	100.0	(6.2)

* Period-on-period movement% represents a comparison between the six months ended June 30, 2026 and the six months ended June 30, 2025. (All amounts are unaudited)



FINANCIAL REVIEW

Revenue

During the first half of 2026, the Group generated revenue primarily from four main business lines, namely (i) precision omni-channel marketing solutions; (ii) physician platform solutions; (iii) RWS solutions; and (iv) data and artificial intelligence solutions. The total revenue of the Group decreased by 6.2% from approximately RMB125.2 million for the six months ended 30 June 2025 to approximately RMB117.5 million during the Reporting Period, mainly attributable to the increasing adoption of AI technology, which reduced demand for certain simple language-based clinical research, leading to a decline in revenue from physician platform solutions.

(i) Precision omni-channel marketing solutions

Revenue from precision omni-channel marketing solutions is primarily derived from fees paid by pharmaceutical and medical device companies in engaging the Group for precision detailing services, medical content creation services and online survey services. Revenue from precision omni-channel marketing solutions increased by approximately 3.4% from approximately RMB56.1 million for the six months ended 30 June 2025 to approximately RMB58.1 million for the same period in 2026, mainly attributable to the accelerated transition of domestic pharmaceutical companies towards evidence-based marketing models, which gradually became the mainstream in the industry.

(ii) Physician platform solutions

Revenue from physician platform solutions is primarily derived from (i) service fees paid by physicians for engaging us for clinical study assistance services; and (ii) subscription fees paid by physicians for accessing certain premium academic medical contents on the MedSci platform. Revenue from physician platform solutions decreased by approximately 30.1% from approximately RMB46.8 million for the six months ended 30 June 2025 to approximately RMB32.7 million for the same period in 2026, mainly driven by the reduced demand for certain simple language-based clinical research due to the popularization of AI technology.

(iii) RWS solutions

Revenue from RWS solutions is primarily derived from service fees paid by pharmaceutical and medical device companies in engaging the Group to design, administer and execute real-world evidence-based research projects to help expand their medical products' indication and recognition. Revenue from RWS solutions increased by approximately 22.6% from approximately RMB16.6 million for the six months ended 30 June 2025 to approximately RMB20.4 million for the same period in 2026, mainly due to the Group's proactive efforts in reducing its inventory orders and enhanced overall efficiency of real-world study through AI applications.



MANAGEMENT DISCUSSION AND ANALYSIS

(iv) Data and artificial intelligence solutions

Revenue from data and artificial intelligence solutions is primarily derived from service fees collected from pharmaceutical and medical device enterprises and consulting companies for the provision of data insights and development and use of artificial intelligence products. Revenue from data and artificial intelligence solutions increased by approximately 11.2% from approximately RMB5.6 million for the six months ended 30 June 2025 to approximately RMB6.3 million for the same period in 2026, mainly due to the increase in the demand for relevant products and services in the industry.

Cost of Sales

Our cost of sales primarily consists of (i) staff salaries and benefits relating to employee benefit expenses incurred for employees involved in operating our platform and offering our solutions to customers; (ii) content development costs primarily relating to content development fees paid to various content contributors, copyright owners and other third parties to produce contents for our solutions offering; (iii) meeting affair charge relating to offline academic conferences we organised; and (iv) various other miscellaneous expenses such as, among others, office expenses and depreciation and amortization incurred during the ordinary course of our business. Our cost of sales increased by approximately 17.5% from approximately RMB47.8 million for the six months ended 30 June 2025 to approximately RMB56.1 million for the same period in 2026, mainly because (i) the revenue structure has shifted, with the proportion of high-margin physician platform solutions declining; and (ii) against the backdrop of industry cost-containment, project pricing has trended downward, customer acquisition costs have risen, compressing profit margins.

Gross Profit and Gross Profit Margin

As a result of the foregoing, our gross profit decreased by approximately 20.8% from approximately RMB77.5 million for the six months ended 30 June 2025 to approximately RMB61.3 million for the same period in 2026. For the six months ended 30 June 2026, our gross profit margin was approximately 52.2%, representing a decrease as compared to 61.9% for the same period in 2025.

Other Income and Gains

Our other income primarily consists of (i) bank interest income; (ii) tax incentives granted by local authorities; (iii) government grants; and (iv) others. We also recognized gains for the six months ended 30 June 2026, which primarily include (i) foreign exchange gains; and (ii) fair value gains on financial assets at fair value through profit or loss. For the six months ended 30 June 2026, our other income and gains were approximately RMB15.5 million, as compared to approximately RMB20.6 million for the same period in 2025. The decrease was mainly attributable to downward bank interest rates, as bank interest income fell from approximately RMB7.3 million to approximately RMB3.2 million.

Selling and Distribution Expenses

Our selling and distribution expenses primarily consist of (i) staff salaries and benefits mainly including expenses paid to employees performing selling and distribution functions; (ii) traveling expenses mainly including traveling fees incurred by our employees in performing selling and distribution functions; (iii) professional fees in relation to fees paid to external lecturers in hosting our online courses; (iv) business development expenses mainly including marketing-associated costs in relation to various online and offline campaigns; and (v) other miscellaneous expenses, such as, office expenses and depreciation and amortisation in relation to property, office equipment and electronic equipment in association with selling and distribution functions. Our selling and distribution expenses decreased by approximately 29.0% from approximately RMB33.8 million for the six months ended 30 June 2025 to approximately RMB24.0 million for the same period in 2026, mainly attributable to the enhancement of efficiency of sales personnel and the improvement in the refined management capability of the Company.

MANAGEMENT DISCUSSION AND ANALYSIS



Administrative Expenses

Our administrative expenses primarily consist of (i) staff salaries mainly including salaries and benefits paid to employees performing administrative functions; (ii) depreciation and amortisation in relation to property, office equipment and electronic equipment in association with administrative functions; (iii) external consulting fees in relation to auditing fees, service fees paid for external training and service fees paid to employment agencies; (iv) office expenses in relation to administrative functions; and (v) other miscellaneous fees such as travelling expenses and utility expenses incurred during the ordinary course of our business when performing administrative functions. Our administrative expenses decreased by approximately 19.5% from approximately RMB22.6 million for the six months ended 30 June 2025 to approximately RMB18.2 million for the same period in 2026, mainly attributable to the improvement in administrative efficiency resulting from the application of AI tools in internal operations and refined management, as well as the decrease in share-based payment expenses.

Research and Development Expenses

Our research and development expenses primarily consist of (i) employee salaries and benefits, which primarily include salaries and benefits paid to employees performing research and development duties; (ii) depreciation and amortisation of properties, office equipment and electronic equipment related to research and development functions; (iii) technical service fees in relation to research and development service fees; (iv) procurement fees for software and servers, etc. related to research and development activities; and (v) other miscellaneous expenses. Our research and development expenses decreased by approximately 26.3% from approximately RMB19.7 million for the six months ended 30 June 2025 to approximately RMB14.5 million for the same period in 2026, mainly due to the Group's full utilisation of AI tools to support research and development, which enhanced R&D efficiency.

Impairment Losses on Financial and Contract Assets

Impairment losses on financial and contract assets arise primarily from impairments of trade receivables, contract assets and other assets. For the six months ended 30 June 2025 and 2026, we had impairment losses on financial and contract assets of approximately RMB7.4 million and RMB9.0 million, respectively. An impairment analysis is performed at the end of each of reporting periods using a provision matrix to measure expected credit losses. The provision rates are based on aging and past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the end of each of reporting periods about past events, current conditions and forecasts of future economic conditions.

Finance Costs

Our finance costs primarily represent interest on the Group's lease liabilities. We recorded finance costs of approximately RMB92,000 and RMB504,000 for the six months ended 30 June 2025 and 2026, respectively. The year-on-year movement primarily reflected the net effect of new, renewed and expiring lease arrangements during the period.

Profit Before Tax

As a result of the foregoing, we generated profit before tax of approximately RMB10.4 million for the six months ended 30 June 2026 as compared to a profit before tax of approximately RMB14.5 million for the six months ended 30 June 2025.



MANAGEMENT DISCUSSION AND ANALYSIS

Income Tax Credit/(Expense)

We recorded an income tax credit of approximately RMB0.2 million for the six months ended 30 June 2026, compared with income tax expense of approximately RMB1.3 million for the same period in 2025, mainly attributable to nil current tax expense during the period and the recognition of deferred tax credits.

Profit for the Period and Profit Attributable to Owners of the Parent

As a result of the foregoing, we generated profit for the period of approximately RMB10.6 million for the six months ended 30 June 2026 as compared to approximately RMB13.2 million for the same period in 2025, while the profit attributable to owners of the parent for the six months ended 30 June 2025 and 2026 was approximately RMB13.2 million and RMB10.6 million, respectively. Our net profit margin (calculation of which is based on profit for the period) decreased from approximately 10.6% for the six months ended 30 June 2025 to approximately 9.0% for the same period in 2026.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended 30 June 2026, we mainly financed our future capital requirements through cash generated from our business operations, and the net proceeds from the Global Offering. We currently do not anticipate any changes to the availability of financing to fund our operations in the near future.

The unutilised portion of the net proceeds raised by the Company from the Global Offering was placed with the licensed financial institutions as short-term deposits.

Cash and Cash Equivalents

The Group operates its business in China and its transactions and revenue are primarily denominated in Renminbi. As such, the Group did not have material exposure to fluctuations in foreign currency exchange rates for cash generated from its operating activities. However, the net proceeds received by the Company from the Global Offering are denominated in Hong Kong dollars and the Company is exposed to fluctuation of exchange rate between RMB and Hong Kong dollars. The net proceeds raised by the Group from the Global Offering in April 2023 was approximately HKD526.8 million. As at 30 June 2026, the Group's cash and cash equivalents amounted to approximately RMB329.6 million (mainly including cash at banks), as compared to approximately RMB367.7 million as at 31 December 2025.

The Group currently does not have any hedging policy for foreign currencies in place. However, the Board will remain alert to any relevant risks and, if necessary, consider to hedge any material potential foreign exchange risk.

Banking Facilities

For the six months ended 30 June 2026, we did not have any banking borrowings or other interest-bearing borrowings, nor did we have outstanding bank and other borrowings and other debts, save for the lease liabilities for the relevant lease terms amounting to approximately RMB5.4 million in aggregate.



Financial Assets at Fair Value through Profit or Loss

The Group's financial assets at fair value through profit or loss decreased from approximately RMB809.6 million as at 31 December 2025 to approximately RMB669.8 million as at 30 June 2026, primarily due to the redemption of certain wealth management products.

As part of the Group's treasury management, the Group may from time to time purchases low to medium-risk wealth management products using internal resources without utilising proceeds from the Global Offering to improve utilisation of the Group's cash on hand on a short-term basis. The Group has implemented internal policies and rules setting out overall principles and the approval process to manage such investment activities. Details of the Group's internal investment policy is set out in the section headed "Significant Investments, Acquisition and Disposals — Investment Policy" in this report.

Gearing Ratio

As at 30 June 2026, the gearing ratio, which is calculated by dividing borrowings by total equity, is zero as there was no debt.

Capital Expenditure

As at 30 June 2026, we did not have any significant capital expenditure.

Capital Commitment

As at 30 June 2026, we did not have any significant capital commitment.

Contingent Liabilities

As at 30 June 2026, we did not have any material contingent liabilities.

Charge on Assets

As at 30 June 2026, we did not pledge any of our assets.



MANAGEMENT DISCUSSION AND ANALYSIS

Continuing Disclosure Obligations Pursuant to the Listing Rule

As of the date of this interim report, the Company did not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

Employees, Staff Costs and Remuneration Policies

As of the date of this interim report, the Group has a total of 396 full-time employees, all of whom are based in China. In particular, 9 employees are responsible for the Group's management, 153 employees for platform operation and customer services, 81 employees for research and development, 25 employees for general and administration, and 128 employees for sales and marketing.

For the six months ended 30 June 2026, the total staff cost incurred by the Group was approximately RMB54.4 million, as compared to approximately RMB70.1 million for the same period in 2025.

The Group provides our employees with salaries and bonuses, as well as employee benefits, including employee retirement benefit schemes, medical and vocational injury insurance schemes and housing provident fund schemes. Our employees located in China are covered by the mandatory social security schemes defined by PRC local practice and regulations, which are essentially defined contribution schemes.

The Group provides orientation and training to new recruits as well as ongoing in-house training for junior employees, which the Group believes can enhance the skills and productivity of its employees. The Group compensates employees with base salaries and performance-based bonuses.

OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company is committed to maintaining and promoting high standards of corporate governance, which is essential to the Company's development and protection of the interests of its shareholders. The Company has adopted the relevant code provisions of the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as the basis for its corporate governance practices.

The Board is of the view that the Company has complied with all the applicable code provisions as set out in the CG Code during the six months ended 30 June 2026 which were then in force. The Board will continue to review and monitor the corporate governance practices of the Company with the aim of maintaining a high standard of corporate governance.

Compliance with Model Code for Securities Transactions

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its code of conduct regarding dealings in the securities of the Company by the Directors and the Group's employees who, because of his/her office or employment, are likely to possess inside information. Specific enquiries have been made by the Company to all Directors, and the Directors have confirmed that they have complied with the Model Code during the six months ended 30 June 2026. No incident of non-compliance of the Model Code by the employees was identified by the Company during the six months ended 30 June 2026.

MANAGEMENT DISCUSSION AND ANALYSIS



Directors' Interest in Competing Business

During the six months ended 30 June 2026, none of the Directors or their respective associates had engaged in or had any interest in any business which competes or may compete with the business of the Group.

Purchase, Sale or Redemption of Listed Securities

For the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares).

As at 30 June 2026, neither the Company nor any of its subsidiaries held treasury shares.

Issue of Equity Securities

During the six months ended 30 June 2026, the Company did not issue any equity securities (including securities convertible into equity securities) or sale of treasury shares for cash.

Use of Proceeds

The shares (the "Shares") of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 27 April 2023 (the "Listing Date") at HKD9.10 per share, with net proceeds received by the Company from the Global Offering in the amount of approximately HKD526.8 million after deducting underwriting commissions and all related expenses. The following table sets forth the Company's use of the proceeds from the Global Offering as at 30 June 2026:

Use	Approximate % of the total net proceeds	Net proceeds from the Global Offering HKD'million	Unutilised amount (as at 1 January 2026) HKD'million	Utilised amount (from 1 January 2026 to 30 June 2026) HKD'million	Unutilised amount (as at 30 June 2026) HKD'million
Business expansion	45	237.1	232.1	—	232.1 ⁽²⁾
Further technology development	35	184.4	108.8	14.5	94.3 ⁽²⁾
Potential investments and acquisitions or strategic alliance with companies that can generate synergies with our business	15	79.0	71.6	—	71.6
Working capital and general corporate purposes	5	26.3	—	—	—
Total	100.0	526.8	412.5	14.5	398.0

Notes:

- (1) The expected timeline of full utilisation is based on the Directors' best estimation barring unforeseen circumstances.
- (2) According to the Prospectus, certain parts of the net proceeds were expected to be utilised before December 2024. Taking into account the Group's operation and financial status, the expected time to fully utilise the net proceeds for "Business expansion" and "Further technology development" has been updated to December 2026.



MANAGEMENT DISCUSSION AND ANALYSIS

As at 30 June 2026, the unutilised net proceeds as at 30 June 2026 amounted to HKD398.0 million and, save as disclosed, the Group planned to utilise the net proceeds in accordance with the intended purposes and timeline as stated in the Prospectus by the end of 2026.

Significant Investments, Acquisition and Disposals

Save for investment in subsidiaries, the significant investments held by the Group as at 30 June 2026 (i.e. investments with a carrying amount accounting for 5% or more of the Group's total assets) are set out below:

Name of issuer	Nature of investment	Costs of acquisition/ investment (approximate HK\$'000)	Fair value as at 30 June 2026 (approximate HK\$'000)	Percentage of the Group's total assets (approximate %)	Unrealised gain/(loss) during the period (approximate HK\$'000)	Realised gain/ (loss) during the period (approximate HK\$'000)	Dividend received/ receivable during the period (approximate HK\$'000)
Huatai International Financial Products Limited (the "Issuer") (Note 1)	Portfolio-linked notes (Note 2)	495,349	501,051	31.95	7,325	—	—

Notes:

1. The Issuer is principally engaged in the issuance of structured products and entering into derivative transactions, and is the issuer of the portfolio-linked notes. Its correspondence address in Hong Kong is 62/F, The Center, No.99, Queen's Road, Central, Hong Kong.
2. The performance of such portfolio-linked notes makes reference to interest in the Fund which in turn invests in cash, short-term US treasury bills and other treasury instruments to maintain liquidity and manage cash position.

Types of Investments

The Group's investments include low-risk treasury products such as (a) principal-guaranteed structured deposits offered by licensed banks, whose return rates are partially guaranteed and partially dependent on (among other things) exchange rates of specified currencies; and (b) interest in investment funds managed by licensed fund managers whose value may reflect, among other things, fluctuations in market interest rates and/or values of money market bonds. The Group may also engage banks to provide discretionary trading services to its idle cash provided the mandate shall only cover low-risk products such as major currencies, government and corporate bonds, and other fixed income/treasury instruments.

Structured deposits generally have an annualized return rate between 1.5% and 4.5%, and a maturity of 6 to 12 months. Interests in investment funds may generally have an expected annualized return rate between 3.5% and 4.5%, and have a lock-up period of 6 to 12 months. To the Group's knowledge and belief, these investment funds mainly invests in major currencies, government and corporate bonds, and other fixed income/treasury instruments. These investments are managed by licensed fund managers with sufficient experience in bonds, treasury or fixed return instruments; any underlying assets are held by major banks or financial institutions as custodians.

Investment Policy

The Company has adopted an internal treasury management and investment policy (the "Investment Policy") which sets out, among other things, the objectives, guidelines, management and responsibilities of investment activities conducted by the Group. Set out below are details of the infrastructure of the Group's investments:



Investment Objectives and Strategies

In order to enhance the efficiency of the Company's capital utilisation, the Company conducts cash management on its temporarily idle funds, and without affecting the intended use of such funds, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The investment strategy of the Company focuses on time deposits, structured deposits with guaranteed returns, and funds investing in treasury instruments, with moderate to low impact of risk factors on the expected return of the investments.

Permissible and Prohibited Investments

The Group's investments are for treasury management purposes only. Permissible investments include time deposits, structured deposits and investment funds linked to currencies, interest rates, government and corporate bonds issued by or supported by licensed banks or major financial institutions. Prohibited investments include equity, leveraged or other derivative financial instruments, speculative investments, and other investment products not within the permissible investments.

Risk Management and Control Measures

The Group identifies and manages the following key risks inherent to the investment instruments/products permitted under the investment policies:

- **Credit risk:** the risk that an issuer, borrower, bank, authorized broker or counterparty fails to meet its obligations, which is especially relevant to bank deposits (bank failure or insolvency), equity securities held through authorised broker (broker default or settlement failure) and debts instruments (issuer default on interest or principal payments). As the Group limits its acquisitions and investments for treasury management purposes to funds and investments issued or managed by major banking and financial institutions, or managed by licensed fund managers with sufficient experience in bonds, treasury or fixed return instruments and whose underlying assets are held by major banks or financial institutions as custodians, the Group considers any counterparty and credit risks to be low.
- **Interest rate risk:** the risk that changes in interest rates adversely affect the value or income of fixed-income investments e.g. fixed deposits or debts instruments bearing fixed-interest rate. To mitigate the interest rate risk, the Group prefers investment products which, though with a moderate to low risk profile, generate a higher return rate upon satisfaction of specific condition(s) linked to interest rate and/or currency exchange rate to compensate such risk.
- **Liquidity risk:** the risk that an investment cannot be sold/converted to cash. To mitigate the liquidity risk, the Group shall only invest in products which have clear redemption mechanism and timeline provisions.
- **Foreign currency exchange rate risk:** the risk of losses from adverse movements in exchange rates for foreign-denominated investments. To mitigate the foreign currency exchange rate risk, the Group shall only invest in products denominated in or linked to global major currencies with relatively stable exchange rates, including USD, HKD, RMB and EUR.



MANAGEMENT DISCUSSION AND ANALYSIS

Defined Risk Limits

While there is no general threshold or restriction in relation to the risk limits or counterparty risk of its investments, the Group is required to adhere to its investment strategy to maintain its investments within an acceptable risk level. In particular, the Group is required to evaluate the counterparty risks of each investment taking into consideration, inter alia, credit ratings of the investment (if any), size and reputation of the issuer, and whether or not the counterparty is a licensed corporation in Hong Kong or overseas.

Liquidity Management

It is the top priority of the Group to ensure that it has sufficient cash and bank deposits to meet its working capital requirement. While there is no specific threshold set under the Investment Policy, the Group seeks to maintain a balanced liquidity profile within its cash, bank deposits and investments. In addition, the use of borrowed funds or those required for ongoing operations for investment purposes is prohibited in the Group. All of the existing investments of the Group were or will be funded by internal resources of the Group.

Ongoing Risk Management and Control Measures

The Group has established comprehensive internal control and risk management frameworks, including regular performance reviews, stringent approval workflows and ongoing monitoring of all investments. The Group's dedicated treasury management team in the Finance Department is responsible for ongoing monitoring of the investments made by the Group and periodic reassessment of counterparties and/or investment targets. The Finance Department is also responsible for maintaining complete and accurate records of all investments, and should immediately notify the Investment Committee of any material adverse changes in the Group's investment, and the materiality of such changes shall be assessed on a case-by-case basis according to the nature and scale of the specific investment.

The Board established the Investment Committee, which comprises two executive Directors and one of the joint company secretaries of the Company, with delegated authority to review and approve the acquisition and disposal of the Group's investments for treasury management purposes. All investment decisions must be approved by the Investment Committee. The following steps outline the internal control procedures as at 30 June 2026:

- Step 1: Origination & Preliminary Screening — The process begins when the Finance Department identifies a potential investment. The Finance Department promptly conducts a high-level review, and instructs the Compliance Department to prepare size test. They assess the opportunity's basic strategic fit and potential conflicts of interest, such as any pre-existing relationships with the target. Based on this initial evaluation, the Finance Department decides whether to reject the opportunity or approve it for formal due diligence.
- Step 2: Due Diligence & Analysis — For opportunities moving forward, a focused due diligence phase is initiated. The Finance Department conducts the commercial assessment, evaluating strategic alignment and synergies, and prepares financial analysis to validate viability and risks. External experts are engaged for legal or technical reviews as needed. The findings from this phase form the direct basis for the final decision.
- Step 3: Approval & Final Decision — All investment decisions must be approved by the Investment Committee. The Finance Department presents the due diligence findings to the Investment Committee, with the financial manager present to support the financial analysis, leading to the Investment Committee's final vote. After the final decision of the Investment Committee, the Compliance Department and the joint company secretaries should prepare the necessary filing and announcement, if any, under the regulatory requirements of the Listing Rules.

MANAGEMENT DISCUSSION AND ANALYSIS



Save as disclosed above, there were no significant investments held by the Group as at 30 June 2026. The Group had no other material acquisitions or disposal of subsidiaries, associates and joint ventures during the Reporting Period.

Future Plans for Material Investments and Capital Assets

Save as disclosed in the aforementioned section headed “Use of proceeds” in this interim report, the Group did not have plan for material investments and capital assets as at the date of this interim report.

Changes to Directors’ Information

Pursuant to Rule 13.51B(1) of the Listing Rules, there have been no changes in Directors’ information required to be disclosed, since publication of the Group’s 2025 Annual Report up to the date of publication of this interim report.

Foreign Exchange Exposure

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect our financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars and the U.S. dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars and the U.S. dollars, has been based on rates set by the People’s Bank of China. The Group primarily limits our exposure to foreign currency risk by closely monitoring the foreign exchange market. For the six months ended 30 June 2026, the Group did not enter into any currency hedging transactions. During the period, the Group’s other comprehensive income mainly comprised exchange differences arising from the translation of the financial statements of overseas operations. For the six months ended 30 June 2026, the RMB appreciated significantly against the Hong Kong dollar and the U.S. dollar compared with the same period in 2025. As a result, when the net assets of the Group’s overseas operations denominated in Hong Kong dollars and U.S. dollars were translated into RMB, a translation loss of RMB319,000 arose, compared with a translation loss of RMB57,000 in the same period in 2025, representing a year-on-year increase of RMB262,000. This change was primarily attributable to the significantly larger appreciation of the RMB against the Hong Kong dollar and the U.S. dollar during the period compared with the same period last year, which led to a corresponding increase in the translation loss.



MANAGEMENT DISCUSSION AND ANALYSIS

Directors' and Chief Executive's Interests or Short Positions in Shares, Underlying Shares and Debentures of the Company and Its Associated Corporations

As at 30 June 2026, the interests and short positions of the Directors and the chief executive of the Company in the Shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) as notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she is keen to taken or deemed to have under such provisions of the SFO), or as recorded in the registered maintained by the Company under Section 352 of the SFO, or as notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

(a) Interest in Shares of the Company

Name	Capacity/Nature of Interest	Number of Shares/ underlying Shares as at 30 June 2026 ⁽¹⁾	Approximate percentage of shareholding in the Company as at 30 June 2026 ⁽²⁾
Dr. Li Xinmei (李欣梅博士)	Interest in a controlled corporation	177,929,750(L) ⁽³⁾	29.30%
	Interest of spouse	165,189,250(L) ⁽³⁾	27.21%
Dr. Zhang Fabao (張發寶博士)	Interest in a controlled corporation	140,972,700(L) ⁽⁴⁾	23.22%
	Interest in a controlled corporation	24,216,550(L) ⁽⁴⁾	3.99%
	Interest of spouse	177,929,750(L) ⁽⁴⁾	29.30%

Notes:

- (1) The letter "L" denotes the person's long position in the Shares.
- (2) The calculation is based on a total of 607,170,950 Shares in issue as at 30 June 2026.
- (3) Microhealth Limited is wholly owned by Dr. Li and Dr. Li beneficially holds 177,929,750 Shares. By virtue of the SFO, Dr. Li is deemed to be interested in the Shares held by Microhealth Limited. As Dr. Zhang is the spouse of Dr. Li, Dr. Li is deemed to be interested in the Shares in which Dr. Zhang is interested by virtue of the SFO, being 165,189,250 Shares.
- (4) Dtx Health Limited is wholly owned by Dr. Zhang and Dr. Zhang beneficially holds 140,972,700 Shares. By virtue of the SFO, Dr. Zhang is deemed to be interested in the Shares held by Dtx Health Limited. As Dr. Li is the spouse of Dr. Zhang, Dr. Zhang is deemed to be interested in the Shares in which Dr. Li is interested by virtue of the SFO, being 177,929,750 Shares. Meilong Limited is one of our employee equity incentive platforms, which is held as to approximately 44.67% by Dr. Zhang (including approximately 2.58% held through Dtx Health Limited) as at 30 June 2026, and beneficially held 24,216,550 Shares. By virtue of the SFO, Dr. Zhang is deemed to be interested in the Shares held by Meilong Limited.

MANAGEMENT DISCUSSION AND ANALYSIS



(b) Interest in shares of the Company's associated corporations

Name	Capacity/ Nature of Interest	Associated Corporations	Amount of registered capital (RMB)	Approximate percentage of interest in the associated corporation
Dr. Li	Beneficial interest	Shanghai MedSci	3,630,408	36.11%
	Interest of spouse	Shanghai MedSci	3,316,585 ⁽¹⁾	32.99%
	Interest of spouse	Hefei Kang'en	990,000 ⁽¹⁾	99.00%
Dr. Zhang	Beneficial interest	Shanghai MedSci	2,832,254	28.17%
	Interest in a controlled corporation	Shanghai MedSci	484,331 ⁽²⁾	4.82%
	Interest of spouse	Shanghai MedSci	3,630,408 ⁽³⁾	36.11%
	Beneficial interest	Hefei Kang'en	990,000	99.00%

Notes:

- (1) As Dr. Zhang is the spouse of Dr. Li, Dr. Li is deemed to be interested in the registered capital of Shanghai MedSci MedTech Co., Ltd.* (上海梅斯醫藥科技有限公司) ("Shanghai MedSci") and Hefei Kang'en Information Technology Co., Ltd.* (合肥康恩信息技術有限公司) ("Hefei Kang'en") (Shanghai MedSci and Hefei Kang'en are our consolidated affiliate entities) held by Dr. Zhang by virtue of the SFO.
- (2) Shihezi Meilong Equity Investment Partnership (Limited Partnership)* (石河子市梅隆股權投資合夥企業(有限合夥)) ("Meilong Investment"), which is held as to approximately 44.67% by Dr. Zhang as at 30 June 2026, holds RMB484,331 registered capital of Shanghai MedSci, in which Dr. Zhang is deemed to be interested by virtue of the SFO.
- (3) As Dr. Li is the spouse of Dr. Zhang, Dr. Zhang is deemed to be interested in the registered capital of Shanghai MedSci held by Dr. Li by virtue of the SFO, being RMB3,630,408.

Save as disclosed above, as at 30 June 2026, to the knowledge of the Board, none of the Directors or the chief executive of the Company had any interests or short positions in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors and the chief executive of the Company were taken or deemed to have under such provisions of the SFO); (ii) recorded in the register kept by the Company pursuant to Section 352 of the SFO; or (iii) notified to the Company and the Stock Exchange pursuant to the Model Code.



MANAGEMENT DISCUSSION AND ANALYSIS

Interests and Short Positions of Substantial Shareholders in the Shares and Underlying Shares of the Company

As at 30 June 2026, so far is known to, or can be ascertained after reasonable enquiry by the Directors, the following persons/entities have interests and/or short positions in our Shares or our underlying Shares which would fall to be disclosed to the Company and the Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO, or are directly or indirectly interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or any other member of the Group:

Name of Substantial Shareholder	Capacity/Nature of Interest	Number of Shares/ Underlying Shares as at 30 June 2026 ⁽¹⁾	Approximate percentage of shareholding in the Company as at 30 June 2026
Microhealth Limited	Beneficial interest	177,929,750(L) ⁽²⁾	29.30%
Dtx Health Limited	Beneficial interest	140,972,700(L) ⁽³⁾	23.22%
Ms. Yu Jia (于佳)	Interest in a controlled corporation	65,983,400(L) ⁽⁴⁾	10.87%
Mr. Hu Xu Bo (胡旭波)	Interest in a controlled corporation	53,865,750(L) ⁽⁴⁾	10.87%
Dragon Step Ventures Limited	Beneficial interest	53,865,750(L) ⁽⁴⁾	8.87%
Qiming Ronghe	Interest in a controlled corporation	53,865,750(L) ⁽⁴⁾	8.87%
Suzhou Qicheng	Interest in a controlled corporation	53,865,750(L) ⁽⁴⁾	8.87%
Shanghai Qichang	Interest in a controlled corporation	53,865,750(L) ⁽⁴⁾	8.87%
Meiyue Limited	Beneficial interest	37,306,505(L) ⁽⁵⁾	6.14%
Image Frame Investment (HK) Limited	Beneficial interest	37,700,750(L) ⁽⁶⁾	6.21%
Tencent Holdings Limited	Interest in a controlled corporation	37,700,750(L) ⁽⁶⁾	6.21%

Notes:

- (1) The letter "L" denotes the person's long position in the Shares.
- (2) Microhealth Limited is wholly owned by Dr. Li.
- (3) Dtx Health Limited is wholly owned by Dr. Zhang.
- (4) Dragon Step Ventures Limited is 100% held by Suzhou Qiming Ronghe Venture Capital Investment Partnership (Limited Partnership)* (蘇州啟明融合創業投資合夥企業(有限合夥)) ("Qiming Ronghe"). Qiming Ronghe is controlled by Suzhou Qicheng Investment Management Partnership (Limited Partnership)* (蘇州啟承投資管理合夥企業(有限合夥)) ("Suzhou Qicheng"), which is in turn controlled by Shanghai Qichang Investment Consulting Co., Ltd.* (上海啟昌投資諮詢有限公司) ("Shanghai Qichang"), a company held as to 50% and 50% by Mr. Hu Xubo and Ms. Yu Jia, respectively. Therefore, Mr. Hu Xubo and Ms. Yu Jia are deemed to be interested in the Shares held by Dragon Step Ventures Limited by virtue of the SFO.



- (5) Meiyue Limited is one of our employee equity incentive platforms and beneficially held 37,306,505 Shares. Each of the shareholders of Meiyue Limited, being an employee of the Group, held less than 20% equity interests in Meiyue Limited.
- (6) Image Frame Investment (HK) Limited is ultimately controlled by Tencent Holdings Limited, a company listed on the Stock Exchange (stock code: 700), and beneficially held 37,700,750 Shares. By virtue of the SFO, Tencent Holdings Limited is deemed to be interested in the Shares held by Image Frame Investment (HK) Limited.

Save as disclosed above, as at 30 June 2026, the Directors were not aware of any other persons/entities (other than the Directors and chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

Equity Incentive plan

On 20 April 2022, the Company adopted an equity incentive plan (“**Equity Incentive Plan**”), the terms of which are not subject to the provisions of Chapter 17 of the Listing Rules as they do not involve the grant of options by the Company after its Listing Date and all shares underlying these awards had been issued. All grants of award shares of the Company have been completed before its Listing Date.

Purposes of the Equity Incentive Plan

The purpose of the Equity Incentive Plan is to attract and retain talents to facilitate our long-term development thereof. The Board may amend, suspend or terminate the Equity Incentive Plan. The decision of the Board with respect to any matter arising under the Equity Incentive Plan (including the interpretation of any provision) shall be final and binding.

Eligibility

The directors (excluding independent non-executive directors), senior management and employees of the Group, whom the Board considers as appropriate (the “**Participants**”) shall be eligible to participate the Equity Incentive Plan.

Administration of the Equity Incentive Plan

The Equity Incentive Plan shall be subject to the administration of the Board in accordance with the plan rules thereof. The Board may amend, suspend or terminate the Equity Incentive Plan. The decision of the Board with respect to any matter arising under the Equity Incentive Plan (including the interpretation of any provision) shall be final and binding.

Grant of Awards and Voting Rights

Ma Yanqin (馬艷芹) is the sole director of Meilong Limited. Thus, in effect, all management powers over Meilong Limited and voting rights held by Meilong Limited in the Company reside with Ma Yanqin. Wu Zhihua (吳志華) is the sole director of Meiyue Limited. Thus, in effect, all management powers over Meiyue Limited and voting rights held by Meiyue Limited in the Company reside with Wu Zhihua. All grants under the Equity Incentive Plan were completed. All Participants do not have any voting rights in the Company. The Participants will be granted awards in the form of economic interest in the Employee Equity Incentive Platforms conditional upon certain vesting conditions as specified in the Equity Incentive Plan.



MANAGEMENT DISCUSSION AND ANALYSIS

Restriction on Disposal

The economic interests shall be realized through disposal of the awarded Shares by the relevant employee equity incentive platforms, the economic interest of no more than 20% of the Shares underlying the award to a Participant could be realised per year.

Details of the Awards under the Equity Incentive Plan

As at 30 June 2026, Meiyue Limited held 37,306,505 Shares and Meilong Limited held 21,622,628 Shares, with interest attributable to certain Directors and employees of our Group through their respective employee equity incentive platforms, representing approximately 9.71% of the issued share capital of our Company. The Participants made capital contributions to and hence hold economic interests in the employee equity incentive platforms, which in turn hold economic interests in the Company. Hence, the Participants hold indirect economic interests in the Shares issued and awarded under the Equity Incentive Plan.

The following table sets out the number of underlying shares corresponding to the interests in the relevant employee equity incentive platforms.

Name of Participants	Position held within the Group	Relevant employee incentive platform	Approximate percentage of interest in the relevant Employee Equity Incentive Platform
Directors			
Dr. Zhang Fabao	Executive Director and chairman of the Board	Meiyue Limited	12.69%
		Meilong Limited	44.67% ⁽¹⁾
Mr. Wang Shuai (王帥)	Executive Director and Co-Chief Executive Officer	Meiyue Limited	14.95%
Other Participants, who are not our directors, chief executive, or connected person	—	Meiyue Limited	72.36%
		Meilong Limited	55.33%

Note:

- (1) This included approximately 2.58% interests in Meilong Limited held by Dr. Zhang through Dtx Health Limited as at 30 June 2026.



Share Award Scheme

On 19 September 2023, the Company adopted a share award scheme (the “**Share Award Scheme**”). Further details of the Share Award Scheme were set out in the announcement of the Company dated 19 September 2023.

Purpose of the Share Award Scheme

The purposes of the Share Award Scheme are to recognise the contributions by certain Eligible Participants (as defined below) and to provide them with incentives in order to retain them for the continual operation and development of the Group; and to attract suitable personnel for further development of the Group.

Eligible Participants

Eligible participants of the Share Award Scheme (the “**Eligible Participants**”) include the following: (i) directors and employees (including full-time employees and part-time employees) of the Company or any of its subsidiaries (including persons who are granted awards under the Share Award Scheme as an inducement to enter into employment contracts with these companies); (ii) directors and employees of the holding companies, fellow subsidiaries or associated companies of the Company; and (iii) persons who provide services to the Company and/or its subsidiaries on a continuing or recurring basis in its ordinary and usual course of business which are in the interests of the long-term growth of the Company and/or its associated companies. For the avoidance of doubt, service providers may not include placing agents or financial advisers providing advisory services for fundraising, mergers or acquisitions, as well as professional service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity.

Duration

Subject to any early termination as may be determined by the Board pursuant to the rules relating to the Share Award Scheme, the Share Award Scheme shall be valid and effective for a term of 10 years commencing on the adoption date, i.e. 19 September 2023 (“**Adoption Date**”), after which no further awards will be granted. As at the date of this interim report, the remaining life of the Share Award Scheme is approximately seven years.

Administration

The Share Award Scheme is subject to the administration by the Board and Futu Trustee Limited (“**Trustee**”), a professional trustee appointed under the trust deed in accordance with the rules of the Share Award Scheme and the terms of the trust deed.



MANAGEMENT DISCUSSION AND ANALYSIS

Operation of the Share Award Scheme

The Board may, from time to time, at its sole and absolute discretion select any Eligible Participant (other than any Excluded Participant) for participation in the Share Award Scheme as a Selected Participant, and grant an Award to any Selected Participant at such consideration (if any) subject to such terms and conditions as the Board may in its sole and absolute discretion determine, including (among others) the amount of and the basis determining, if any, any purchase price payable on application or acceptance of the Award Shares and the period within which any payments or calls must or may be made or any loan for such purposes must be repaid.

The Board may from time to time cause to be paid a Contributed Amount to the Trust by way of settlement or otherwise contributed by the Company, any Subsidiary, any Significant Shareholder or any party designated by the Company as directed by the Board which shall constitute part of the trust fund, for the purchase of Shares and other purposes set out in the Scheme Rules and the Trust Deed.

Subject to prior written direction and/or consent of the Board, the Trustee may accept Shares transferred, gifted, assigned, or conveyed to the Trust from any Significant Shareholder or any party designated by the Company from time to time in such number as such Significant Shareholder or such party designated by the Company may at their sole and absolute discretion determine, which shall constitute part of the trust fund.

Subject to the rules relating to the Share Award Scheme, the Board may from time to time instruct the Trustee in writing to purchase Shares on the Stock Exchange or accept and receive a specified number of Shares from any Significant Shareholder or any party designated by the Company. Once purchased or received, the Shares are to be held by the Trustee for the benefit of the Selected Participants under the Trust until they are vested, on and subject to the terms and conditions of the Share Award Scheme and the Trust Deed. On each occasion when the Board instructs the Trustee to purchase Shares on the Stock Exchange, it shall specify the maximum amount of funds to be used and the range of prices at which such Shares are to be purchased. The Trustee may not incur more than the maximum amount of funds or purchase any Shares at a price falling outside the range of prices so specified unless with the prior written consent of the Board.

Vesting and lapse

Subject to the terms and conditions of the Share Award Scheme and the fulfillment of all vesting conditions applicable to the vesting of the Awarded Interests on such Selected Participant, the respective Awarded Interests held by the Trustee on behalf of the Selected Participant pursuant to the provision thereof shall vest in such Selected Participant in accordance with the applicable vesting schedule, and the Trustee shall cause the Awarded Interests to be transferred to such Selected Participant and/or a vehicle controlled by him/her (such as a trust or a private company) for the benefit of the Selected Participant and any family members of such Selected Participant in accordance with the Scheme Rules. In the event that a Selected Participant is a director, a substantial shareholder or a connected person of the Group, such Awards shall constitute connected transactions under Chapter 14A of the Listing Rules and the Company shall comply with the relevant requirements under the Listing Rules.

MANAGEMENT DISCUSSION AND ANALYSIS



Unless the Board determines otherwise in accordance with the rules relating to the Share Award Scheme, in the event of the following matters, all relevant Award(s) made to such Selected Participant shall automatically lapse and the relevant Awarded Shares shall not vest on the relevant vesting date but shall remain part of the trust fund: (i) Selected Participant is found to be an Excluded Participant; (ii) where such person has committed any act of fraud or dishonesty or serious misconduct, whether or not in connection with his employment or engagement by any member of the Group and whether or not it has resulted in his employment or engagement being terminated by the relevant member of the Group; (iii) where such person has been declared or adjudged to be bankrupt by a competent court or governmental body or has failed to pay his debts as they fall due or has entered into any arrangement or composition with his creditors generally or an administrator has taken possession of any of his assets; (iv) where such person has been convicted of any criminal offence; (v) where such person has engaged in any act that has had or will have a material adverse effect on the reputation or interests of any member of the Group; or (vi) where such person has been convicted of or is being held liable for any offence under or any breach of the SFO or other securities laws or regulations in Hong Kong or any other applicable laws or regulations in force from time to time.

Reference to “**Awarded Interests**” in this paragraph shall mean in respect of an Award, the (i) Awarded Shares; and/or (ii) such amount of cash from the sale of Shares awarded to him after deduction or withholding of any tax, fees and other charges in connection with the sale of Shares, and the related income (if any) as awarded under the Award. Reference to “**Awarded Shares**” in this paragraph shall mean in respect of a Selected Participant, such number of Shares as awarded to him by the Board. Reference to “**Excluded Participant**” in this paragraph shall mean any Eligible Participant who is resident in a place where the grant of an Award and/or the vesting and transfer of the Awarded Interests pursuant to the terms of the Scheme is not permitted under the laws or regulations of such place or where in the view of the Board or the Trustee (as the case may be), compliance with applicable laws or regulations in such place makes it necessary or expedient to exclude such Eligible Participant.

Scheme limit

The Board shall not make any further award of Awarded Shares which will result in the aggregate number of the Shares awarded by the Board under the Share Award Scheme exceeding 10% of the issued share capital of the Company as at the Adoption Date, which is 60,717,095 Shares, representing 10% of the total issued share capital of the Company as at the date of this interim report.

Limit for each Eligible Participant

The maximum number of Shares which may be awarded to a Selected Participant under the Share Award Scheme shall not exceed 1% of the issued share capital of the Company in any 12-month period. The aforesaid limits shall always be subject to the compliance with the Listing Rules that are in force from time to time, including the requirement on maintaining a minimum public float.

Voting Rights

No instructions shall be given by a Selected Participant (including, without limitation, voting rights) to the Trustee in respect of the Awarded Shares that have not been vested, and such other properties of the trust fund managed by the Trustee. The Trustee shall abstain from exercising the voting rights in respect of any Shares held by it under the Trust (if any) (including but not limited to the Awarded Shares, any bonus Shares and scrip Shares derived therefrom).



MANAGEMENT DISCUSSION AND ANALYSIS

Grant of Awards

During the six months ended 30 June 2026, no share awards were granted by the Company and there were no Awarded Shares which were outstanding or unvested or cancelled or lapsed under the Share Award Scheme during the period.

As at 1 January 2026 and 30 June 2026, the number of Shares available for future grant under the Share Award Scheme was 55,313,275 and 55,313,275, respectively. The number of shares of the Company that may be issued in respect of the Awards granted under the Share Award Scheme during the Reporting Period divided by weighted average number of issued shares of the Company for the Reporting Period was nil as the Share Award Scheme does not and will not involve in issue of any new Shares.

Material Events after the Reporting Period

Save as disclosed in this interim report, there were no other significant events occurred subsequent to 30 June 2026 and up to the date of this interim report.

Audit Committee and Review of Interim Results

The audit committee of the Board (the “**Audit Committee**”) comprises three independent non-executive Directors, namely Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley. The chairwoman of the Audit Committee is Ms. Liu Tao.

The Audit Committee has reviewed this interim report, including unaudited consolidated interim results of the Group for the six months ended 30 June 2026, with the management of the Company. The Audit Committee considered that the unaudited consolidated interim results of the Group for the six months ended 30 June 2026 are in compliance with the applicable accounting standards, laws and regulations. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and issues in relation to internal control, risk management and financial reporting with the management of the Company.

DIVIDENDS

The Board has resolved not to declare an interim dividend for the six months ended 30 June 2026 (same period in 2025: HKD1.1 cents per Share).

By Order of the Board

Dr. Zhang Fabao

Chairman of the Board and Executive Director

MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

29 September 2026



INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026

	Notes	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
REVENUE	4	117,451	125,246
Cost of sales		(56,121)	(47,767)
GROSS PROFIT		61,330	77,479
Other income and gains		15,468	20,618
Selling and distribution expenses		(23,966)	(33,764)
Administrative expenses		(18,212)	(22,618)
Research and development expenses	5	(14,519)	(19,689)
Impairment losses on financial and contract assets		(9,026)	(7,413)
Other expenses		(130)	—
Finance costs		(504)	(92)
PROFIT BEFORE TAX	5	10,441	14,521
Income tax credit/(expense)	6	197	(1,282)
PROFIT FOR THE PERIOD		10,638	13,239
Attributable to owners of the parent		10,638	13,239
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic		RMB1.94 cents	RMB2.45 cents
Diluted		RMB1.94 cents	RMB2.45 cents



INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
OTHER COMPREHENSIVE LOSS		
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:		
Translation difference of the Company's financial statements into presentation currency	(31,078)	(5,473)
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	(856)	(246)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	(31,934)	(5,719)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	(21,296)	7,520
Attributable to owners of the parent	(21,296)	7,520



INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property and equipment	9	14,056	14,559
Right-of-use assets		5,685	6,489
Intangible assets		1,691	1,846
Prepayments and other receivables		5,509	5,518
Deferred tax assets		3,090	2,893
Total non-current assets		30,031	31,305
CURRENT ASSETS			
Trade receivables	10	47,817	41,329
Contract assets		70,703	68,743
Due from a related party	14	2,801	623
Prepayments, deposits and other receivables		5,109	6,342
Financial assets at fair value through profit or loss		669,811	809,605
Time deposits		206,140	10,000
Restricted cash		30	50,030
Cash and bank balances		329,557	367,734
Total current assets		1,331,968	1,354,406
CURRENT LIABILITIES			
Trade payables	11	1,055	3,625
Other payables and accruals		193,971	192,321
Lease liabilities		3,193	2,939
Tax payable		551	2,472
Total current liabilities		198,770	201,357
NET CURRENT ASSETS		1,133,198	1,153,049
TOTAL ASSETS LESS CURRENT LIABILITIES		1,163,229	1,184,354



INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
Lease liabilities		2,235	3,317
Total non-current liabilities		2,235	3,317
NET ASSETS		1,160,994	1,181,037
EQUITY			
Equity attributable to owners of the parent			
Issued capital	12	420	420
Treasury shares		(948)	(948)
Reserves		1,161,522	1,181,565
TOTAL EQUITY		1,160,994	1,181,037



INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2026

	Attributable to owners of the parent									Total RMB'000
	Issued capital RMB'000 (note 12)	Treasury shares RMB'000	Share premium* RMB'000	Capital reserve* RMB'000	Merger reserve* RMB'000	Statutory surplus reserve* RMB'000	Exchange fluctuation reserve* RMB'000	Share- based payment reserve* RMB'000 (note 13)	Accumulated losses* RMB'000	
At 1 January 2026 (Audited)	420	(948)	1,288,979	(1,993)	10,154	7,110	48,801	60,829	(232,315)	1,181,037
Profit for the period	—	—	—	—	—	—	—	—	10,638	10,638
Other comprehensive income for the period:										
Exchange differences on translation of the Company's financial statements	—	—	—	—	—	—	(31,078)	—	—	(31,078)
Exchange differences on translation of foreign operations	—	—	—	—	—	—	(856)	—	—	(856)
Total comprehensive income for the period	—	—	—	—	—	—	(31,934)	—	10,638	(21,296)
Share-based payments	—	—	—	—	—	—	—	1,253	—	1,253
At 30 June 2026 (Unaudited)	420	(948)	1,288,979	(1,993)	10,154	7,110	16,867	62,082	(221,677)	1,160,994

	Attributable to owners of the parent									Total RMB'000
	Issued capital RMB'000 (note 12)	Treasury shares RMB'000	Share premium* RMB'000	Capital reserve* RMB'000	Merger reserve* RMB'000	Statutory surplus reserve* RMB'000	Exchange fluctuation reserve* RMB'000	Share- based payment reserve* RMB'000 (note 13)	Accumulated losses* RMB'000	
At 1 January 2025 (Audited)	420	(582)	1,266,733	(1,993)	10,154	7,110	52,728	85,370	(250,252)	1,169,688
Profit for the period	—	—	—	—	—	—	—	—	13,239	13,239
Other comprehensive income for the period:										
Exchange differences on translation of the Company's financial statements	—	—	—	—	—	—	(5,473)	—	—	(5,473)
Exchange differences on translation of foreign operations	—	—	—	—	—	—	(246)	—	—	(246)
Total comprehensive income for the period	—	—	—	—	—	—	(5,719)	—	13,239	7,520
Share-based payments	—	—	—	—	—	—	—	2,531	—	2,531
At 30 June 2025 (Unaudited)	420	(582)	1,266,733	(1,993)	10,154	7,110	47,009	87,901	(237,013)	1,179,739

* These reserve accounts comprise the consolidated other reserves of RMB1,161,522,000 (31 December 2025: RMB1,181,565,000) in the interim condensed consolidated statement of financial position as at 30 June 2026.



INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

		For the six months ended 30 June	
	Notes	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		10,441	14,521
Adjustments for:			
Interest income	5	(3,168)	(7,303)
Impairment/(reversal of impairment) of trade receivables	5	734	(31)
Impairment of contract assets	5	8,273	7,383
Impairment of other receivables	5	19	61
Depreciation of property, plant and equipment	5, 9	526	593
Depreciation of right-of-use assets	5	1,943	2,299
Amortisation of intangible assets	5	155	169
Fair value gain on financial assets at fair value through profit or loss	5	(9,934)	(9,235)
Finance costs		504	92
Equity-settled share-based payments	5	1,253	2,531
		10,746	11,080
(Increase)/decrease in trade receivables		(7,222)	1,840
Increase in contract assets		(10,233)	(15,555)
Decrease/(increase) in prepayments, deposits and other receivables		1,223	(10)
Decrease in trade payables		(2,570)	(1,468)
Increase in other payables and accruals		1,650	18,159
Decrease/(increase) in restricted deposits		50,000	(10)
Cash from operations		43,594	14,036
Interest received		3,168	7,303
Income tax paid		(1,921)	(620)
Net cash flows from operating activities		44,841	20,719



INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of items of property, plant and equipment	(42)	—
Advance to a key management person	(7,327)	(12,927)
Repayment from a key management person	5,149	7,406
Disposal of items of property and equipment	19	—
Purchase of financial assets at fair value through profit or loss	(179,802)	(110,958)
Redemption of financial assets at fair value through profit or loss	302,182	—
(Decrease)/increase in time deposits with original maturity of more than three months when acquired	(196,140)	50,018
Net cash flows used in investing activities	(75,961)	(66,461)
CASH FLOWS FROM FINANCING ACTIVITIES		
Lease payments (including related interests)	(2,471)	(2,236)
Net cash flows used in financing activities	(2,471)	(2,236)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(33,591)	(47,978)
Cash and cash equivalents at beginning of period	367,734	366,940
Effect of foreign exchange rate changes, net	(4,586)	(3,409)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	329,557	315,553
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS		
Cash and bank balances	329,587	315,583
Time deposits	206,140	234,295
Less: Time deposits with original maturity of more than three months when acquired	206,140	234,295
Restricted deposits	30	30
CASH AND CASH EQUIVALENTS AS STATED IN THE STATEMENT OF CASH FLOWS	329,557	315,553



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

1. CORPORATE INFORMATION

MedSci Healthcare Holdings Limited (the “**Company**”) was incorporated in the Cayman Islands on 22 June 2021 as an exempted company with limited liability under the laws of the Cayman Islands. The registered office address of the Company is 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. The principal place of business of the Group is located at Floor 3, Lane 425, Yishan Road, Xuhui District, Shanghai, China.

The Company is an investment holding company. During the period, the principal activities of the Company and its subsidiaries (collectively referred to as the “**Group**”) were the provision of physician platform solutions, precision omni-channel marketing solutions, real-world study solutions and data and artificial intelligence solutions (collectively the “**Listing Business**”) in the People’s Republic of China (the “**PRC**”).

The shares of the Company have been listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) effective from 27 April 2023.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with IAS 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period’s financial information.

Amendments to IFRS 9 and IFRS 7 *Amendments to the Classification and Measurement of Financial Instruments*

Amendments to IFRS 9 and IFRS 7 *Contracts Referencing Nature-dependent Electricity*

Annual Improvements to IFRS *Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7*

Accounting Standards

— Volume 11

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – *continued*

The nature and impact of the amended IFRS Accounting Standards are described below:

- (a) Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.
- (b) Amendments to IFRS 9 and IFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.
- (c) Annual Improvements to IFRS Accounting Standards – Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

3. OPERATING SEGMENT INFORMATION

The Group is principally engaged in the provision of physician platform solutions, precision omni-channel marketing solutions, real-world study solutions and data and artificial intelligence solutions in Chinese mainland.

IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reporting about components of the Group that are regularly reviewed by the chief operating decision-maker in order to allocate resources to segments and to assess their performance. The information reported to the directors of the Company, who are the chief operating decision-makers, for the purpose of resource allocation and assessment of performance does not contain discrete operating segment financial information and the directors reviewed the financial results of the Group as a whole. Therefore, no further information about the operating segment is presented.

Geographical information

- (a) Revenue from external customers — During the period, substantially all of the Group operated within one geographical location because all of its revenues were generated in the Chinese mainland and all of its long-term assets/capital expenditures were located/incurred in the Chinese mainland. Accordingly, no geographical information is presented.
- (b) Non-current assets — Almost all of the Group's non-current assets as at the end of each reporting period were located in Chinese mainland. Accordingly, no geographical information of segment assets is presented.

Information about major customers

No revenue from the provision of services to a single customer amounted to 10% or more of the total revenue of the Group during the period.

4. REVENUE

An analysis of revenue is as follows:

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue from contracts with customers	117,451	125,246

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



4. REVENUE – continued

(a) Disaggregated revenue information

For the six months ended 30 June 2026

RMB'000 (Unaudited)	Physician platform solutions	Precision omni-channel marketing solutions	Real-world study solutions	Data and artificial intelligence solutions	Total
Types of services					
Provision of services	<u>32,728</u>	<u>58,052</u>	<u>20,390</u>	<u>6,281</u>	<u>117,451</u>
Geographical market					
Chinese mainland	<u>32,728</u>	<u>58,052</u>	<u>20,390</u>	<u>6,281</u>	<u>117,451</u>
Timing of revenue recognition					
Over time	<u>32,728</u>	<u>58,052</u>	<u>20,390</u>	<u>6,281</u>	<u>117,451</u>
Total revenue from contracts with customers	<u>32,728</u>	<u>58,052</u>	<u>20,390</u>	<u>6,281</u>	<u>117,451</u>

For the six months ended 30 June 2025

RMB'000 (Unaudited)	Physician platform solutions	Precision omni-channel marketing solutions	Real-world study solutions	Data and artificial intelligence solutions	Total
Types of services					
Provision of services	<u>46,828</u>	<u>56,140</u>	<u>16,631</u>	<u>5,647</u>	<u>125,246</u>
Geographical market					
Chinese mainland	<u>46,828</u>	<u>56,140</u>	<u>16,631</u>	<u>5,647</u>	<u>125,246</u>
Timing of revenue recognition					
Over time	<u>46,828</u>	<u>56,140</u>	<u>16,631</u>	<u>5,647</u>	<u>125,246</u>
Total revenue from contracts with customers	<u>46,828</u>	<u>56,140</u>	<u>16,631</u>	<u>5,647</u>	<u>125,246</u>



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	Note	For the six months ended 30 June	
		2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Cost of services provided**		39,242	25,473
Depreciation of property and equipment	9	526	593
Depreciation of right-of-use assets		1,943	2,299
Amortisation of intangible assets		155	169
Research and development expenses*		14,519	19,689
Impairment/(reversal of impairment) of financial assets, net:			
— Trade receivables		734	(31)
— Contract assets		8,273	7,383
— Other receivables		19	61
Lease payment not included in the measurement of lease liabilities		—	10
Auditor's remuneration		1,140	1,150
Bank interest income		3,168	7,303
Fair value gain on financial assets at fair value through profit or loss		9,934	9,235
Employee benefit expenses (including directors' and chief executive's remuneration):			
Salaries, bonuses and other allowances		42,393	56,784
Pension scheme contributions and social welfare		12,053	13,280
Equity-settled share-based payments		1,253	2,531
Total		55,699	72,595

* The amounts disclosed for research and development expenses included direct employee and depreciation.

** Cost of services provided represents "Cost of sales" in the consolidated statement of profit or loss excluding right-of-use employee benefit expense, depreciation of property and equipment, depreciation of assets and amortisation of intangible assets.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the tax jurisdictions in which members of the Group are domiciled and operate. Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Company and the Group's subsidiary incorporated in the British Virgin Islands are not subject to any income tax. The Group's subsidiaries incorporated in Hong Kong and the United States were not liable for income tax as the subsidiary in Hong Kong did not have any assessable profits arising in Hong Kong and the subsidiary in the United States has recorded tax losses during the relevant periods. The Singapore company has been established and recorded a loss for income tax purposes during the period.

The provision for current income tax in Chinese mainland is based on a statutory tax rate of 25% of the assessable profits of the PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law, except for Shanghai MedSci MedTech Co., Ltd. ("Shanghai MedSci"), a subsidiary of the Group. Shanghai MedSci was accredited as a high and new technology enterprise ("HNTe") and reapplied for the certification in 2023. As the certification was valid from December 2023 to December 2026. The certification valid for three years. Shanghai MedSci has reapplied for HNTe certification, with the recertification review expected to be concluded in 2026.

	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Current — Chinese mainland:		
Charge for the period	—	2,242
Deferred tax	(197)	(960)
Total tax (credit)/charge for the period	(197)	1,282

7. DIVIDENDS

No interim dividends were paid, declared or proposed during the six months ended 30 June 2026 (six months ended 30 June 2025: HK1.1 cents per ordinary share, amounting to a total of approximately HK\$6,679,000).



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts are based on the profit attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 547,517,022 (six months ended 30 June 2025: 540,682,205) outstanding during the period.

No adjustment has been made to the basic earnings per share amounts presented for the six months ended 30 June 2025 and 2026 for dilution earnings per share amounts as the impact of the unvested shares under the share incentive scheme (note 13) had an anti-dilutive effect on the basic earnings per share amounts presented.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the diluted earnings per share calculation	<u>10,638</u>	<u>13,239</u>
	Number of shares For the six months ended 30 June	
	2026 (Unaudited)	2025 (Unaudited)
Shares		
Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation	<u>547,517,022</u>	<u>540,682,205</u>

The weighted average number of shares was after taking into account the effect of treasury shares held.

9. PROPERTY AND EQUIPMENT

	RMB'000
At 1 January 2026 (Audited)	14,559
Additions	42
Disposals	(19)
Depreciation (Note 5)	<u>(526)</u>
At 30 June 2026 (Unaudited)	<u>14,056</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



10. TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the Reporting Period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Within 1 year	45,640	38,721
1 to 2 years	2,177	2,608
2 to 3 years	—	—
Total	47,817	41,329

11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the Reporting Period, based on the invoice date, is as follows:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Within 3 months	1,055	3,625



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

12. SHARE CAPITAL

	At 30 June 2026		At 31 December 2025	
	Number of shares	RMB'000 (Unaudited)	Number of shares	RMB'000 (Audited)
Authorised:				
Ordinary shares of USD0.0001 each	15,000,000,000	10,361	15,000,000,000	10,361
Issued:				
Ordinary shares of USD0.0001 each	607,170,950	420	607,170,950	420

13. SHARE-BASED PAYMENTS

The Company operates a share award scheme (the “**Scheme**”) for certain personnel in order to recognise and reward the contribution of certain employees of the Group (“**Share Incentive Participants**”) to the growth and development of the Group, and retain certain eligible employees for the continuous operation and development of the Group.

The 2021 Plan

A share incentive plan of Shanghai MedSci (the “**2021 Plan**”) became effective in January 2021. Under the 2021 Plan, Shihezi Meilong Equity Investment Partnership (Limited Partnership) (“**Meilong Investment**”) and Shanghai Meiyue Management Consulting Partnership (Limited Partnership) (“**Shanghai Meiyue**”), the legal shareholders of Shanghai MedSci, granted certain limited partners’ equity interests of Meilong Investment and Shanghai Meiyue (“**Award Interests**”) to certain employees of the PRC Operating Entities. As part of the reorganisation of the Group, the New Plan (see definition below) was adopted to replace the 2021 Plan.

The 2022 Plan

A new share incentive plan (the “**2022 Plan**”) became effective on 20 April 2022 when the board of directors and the shareholders of the Company approved the 2022 Plan, which has replaced the 2021 Plan. The Award Interests granted under the 2021 Plan were replaced and superseded by the ordinary shares of Meilong Limited and Meiyue Limited, respectively (the “**Award Shares**”). The vesting schedule and other key terms of the 2022 Plan are the same as those of the 2021 Plan.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



13. SHARE-BASED PAYMENTS – *continued*

Award Interests

In January 2021, 9.1571% equity interests of Meilong Investment were granted to 19 selected employees for a total consideration of RMB566,000, and 19.90% equity interests of Shanghai Meiyue were granted to 13 selected employees for a total consideration of RMB2,122,000 under the 2021 Plan. These thirty-two employees are collectively referred to as “Share Incentive Participants”.

All of the Award Interests (and the subsequent Award Shares) granted to the Share Incentive Participants are subject to both a listing-based vesting condition (the “**IPO Condition**”) and a service-based vesting condition (the “**Service Condition**”). The IPO Condition have been satisfied when the ordinary shares of the Company are successfully listed on a recognised stock exchange. Subject to the satisfaction of the IPO Condition, the Service Condition would be satisfied over a 5-year lockup period, in which the Award Interests or Award Shares held by Share Incentive Participants shall be unlocked in the proportion up to 20% of the total number of the Award Interests/Shares granted upon the expiry of each of the 5-year lockup periods provided that the IPO Condition is met. Under this Service Condition, the Share Incentive Participants are required to provide services to the Group during the 5-year period.

The Group established two offshore special purpose entities (“**SPEs**”), Meilong Limited and Meiyue Limited, to act as custodian and holding trustee for the Scheme. Under the Scheme, each of Share Incentive Participants holds shares in the relevant SPE, with each shareholding corresponding to a fixed number of the Company’s shares held by the SPE. All such underlying Company’s shares are held in trust for those Share Incentive Participants, with full pro rata beneficial ownership attributable to Share Incentive Participants in their SPE shareholding.

The fair value of the Award Interests granted during the year ended 31 December 2021 was determined at RMB37,297,000, and the Group recognised share-based payment expenses of RMB1,253,000 in profit or loss for the six months ended 30 June 2026 (six months ended 30 June 2025: RMB2,531,000).

The fair value of the Award Interests (and the subsequent Award Shares) granted is measured using a discounted cash flow model at the grant date. The key assumptions used in the model included the discount rate, terminal growth rate and discounts for lack of marketability (“**DLOM**”) and were determined by the directors of the Company with best estimate as follows:

	Granted on 1 January 2021
Discount rate	14%
Terminal growth rate	3%
DLOM	8%



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

13. SHARE-BASED PAYMENTS – *continued*

2023 Plan

On 19 September 2023, the board of directors approved an employee share award scheme (the “**2023 Plan**”) under which: (i) directors and employees (including full-time employees and part-time employees) of the Company or any of its subsidiaries (including persons who are granted awards under the scheme as an inducement to enter into employment contracts with these companies), (ii) directors and employees of the holding companies, fellow subsidiaries or associated companies of the Company, or (iii) persons who provide services to the Company and/or its Subsidiaries on a continuing or recurring basis in its ordinary and usual course of business which are in the interests of the long-term growth of the Company and/or its associated companies. For the avoidance of doubt, service provider may not include placing agents or financial advisers providing advisory services for fundraising, mergers or acquisitions, as well as professional service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity (the “**Eligible Participant**”), will be entitled to participate.

Subject to any early termination as may be determined by the board of directors pursuant to rules of the 2023 Plan (the “**Scheme Rules**”), the 2023 Plan shall be valid and effective for a term of 10 years commencing on 19 September 2023, after which no further awards will be granted.

The 2023 Plan is subject to the administration by the board of directors as settlor and the trustee in accordance with the Scheme Rules and the terms of the trust deed (the “**Trust Deed**”) which was entered into between the Company and the trustee (as restated, supplemented and amended from time to time), namely Future Trustee Limited (the “**Trustee**”).

The board of directors may, from time to time, at its sole and absolute discretion select any Eligible Participant for participation in the 2023 Plan as a selected participant (the “**Selected Participant**”), and grant an award to any Selected Participant at such consideration (if any) subject to such terms and conditions as the board of directors may in its sole and absolute discretion determine.

The board of directors may from time to time cause to be paid an amount of cash to the Trust by way of settlement or otherwise contributed by the Company, any subsidiary, any significant shareholder or any party designated by the Company as directed by the board of directors which shall constitute part of the trust fund, for the purchase of shares and other purposes set out in the Scheme Rules and the Trust Deed.

Subject to the Scheme Rules, the board of directors may from time to time instruct the Trustee in writing to purchase shares on the Hong Kong Stock Exchange (“**Stock Exchange**”) or accept and receive a specified number of shares from any significant shareholder or any party designated by the Company. Once purchased or received, the shares are to be held by the Trustee for the benefit of the Selected Participants under the trust until they are vested, on and subject to the terms and conditions of the 2023 Plan and the Trust Deed.

Subject to the terms and conditions of the Scheme and the fulfilment of all vesting conditions applicable to the vesting of the awarded interests on such Selected Participant, the respective awarded shares held by the Trustee on behalf of the Selected Participant pursuant to the provision thereof shall vest in such Selected Participant in accordance with the applicable vesting schedule, and the Trustee shall cause the awarded interests to be transferred to such Selected Participant and/or a vehicle controlled by him/her (such as a trust or a private company) for the benefit of the Selected Participant and any family members of such Selected Participant in accordance with the Scheme Rules.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



13. SHARE-BASED PAYMENTS – *continued*

2023 Plan – *continued*

On 27 January 2024, the board of directors resolved to grant a total of 5,403,820 awarded shares (“**Awarded Shares**”) to Mr. Fan Jie at Hong Kong Dollar (“**HKD**”) 0.278 per awarded share, for a total consideration of HKD1,502,000. The fair value of Awarded Shares at the grant date was HKD3.13 per shares. The Awarded Shares granted to Mr. Fan Jie represent approximately 0.89% of the issued share capital of the Company as at 27 January 2024, and represent the value of approximately HKD16,914,000, taking into account of the closing price of HKD3.13 per share as stated in the daily quotation sheet issued by the Stock Exchange on 26 January 2024 (being the last trading day prior to the date of grant of the Awarded Shares).

The fair value of the Award Shares granted during the six months ended 30 June 2024 was determined at RMB15,376,000, and the Group recognised expenses of RMB13,998,000 in profit or loss for the six months ended 30 June 2024. As there is no performance target attached to the Awarded Shares granted, no further expense attribution is required for subsequent reporting periods commencing 1 July 2024.

5,265,000 and 400,000 Awarded Shares were acquired during the years ended 31 December 2023 and 2024, respectively, from the market by the Trustee by utilising the Company’s internal resources provided to the Trustee from the market or transferred to the trust by persons in accordance with the rules of the 2023 Plan. On 27 January 2024, 5,241,705 Awarded Shares, have vested to Mr. Fan Jie. No further Awarded Shares were vested since then and Mr. Fan Jie resigned on 25 September 2024.

14. RELATED PARTY TRANSACTIONS

The directors of the Group are of the view that the following parties/companies are related parties that had transactions or balances with the Group during the period.

(a) Transactions with related party

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Non-trade related		
A key management person		
Advance to a key management person	7,327	12,927
Repayment from a key management person	5,149	7,406



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

14. RELATED PARTY TRANSACTIONS – *continued*

(b) Outstanding balances with related party

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Due from a related party:		
Non-trade related		
A key management person	2,801	623

This balance is unsecured, interest free and has no fixed terms of repayment. A key management person was the vice president and one the secretaries of the Company.

(c) Compensation of key management personnel of the Group

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Share-based payment expense	1,253	2,531
Short-term employee benefits	3,759	2,452
Pension scheme contributions	240	263
Total	5,252	5,246

15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of trade receivables, an amount due from a related party, financial assets included in prepayments, deposits and other receivables, cash and bank balances, time deposits, financial assets at fair value through profit or loss, trade payables and financial liabilities included in other payables and accruals, approximate to their carrying amounts largely due to the short term maturities of these instruments.

The Group's corporate finance team is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The corporate finance team reports directly to the board of directors of the Company. At the end of each of the reporting periods, the corporate finance team analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026



15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – *continued*

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The Group invests in unlisted investments, which represent wealth management products and structural deposits issued by segregated portfolio companies in Cayman Islands and premier financial institutions. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow valuation model based on the expected interest rate per annum of instruments with similar terms and risks.

Below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as at 30 June 2026 and 31 December 2025:

	Valuation technique	Significant unobservable input	Range	Sensitivity of fair value to the input
31 December 2025				
Wealth management products	Discounted cash flow	Expected rate of return	2.7%–5.0%	100 basic point increase/decrease in expected rate of return would result in an increase/decrease in fair value by RMB8,957,000
	Valuation technique	Significant unobservable input	Range	Sensitivity of fair value to the input
30 June 2026				
Wealth management products	Discounted cash flow	Expected rate of return	2.7%–5.0%	100 basic point increase/decrease in expected rate of return would result in an increase/decrease in fair value by RMB3,349,000



NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – *continued*

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2026 (unaudited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Financial assets at fair value through profit or loss	—	669,811	—	669,811

As at 31 December 2025 (audited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Financial assets at fair value through profit or loss	—	809,605	—	809,605

16. APPROVAL OF THE INTERIM FINANCIAL INFORMATION

The interim condensed consolidated financial information was approved and authorised for issue by the board of directors on 31 August 2026.